Zamtocabtagene autoleucel for children with B-cell lymphoma or leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new CAR T-cell therapy (zamtocabtagene autoleucel) for children and teens whose B-cell lymphoma or leukemia has come back or hasn't responded to other treatments. The goal is to see if this one-time infusion can help their immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 months and under 18 years old.
- You have a type of B-cell lymphoma or leukemia that didn't respond to treatment or came back after at least one prior therapy.
- Your weight is at least 6 kilograms (about 13 pounds).
- Your cancer shows measurable signs on scans (like a lump that can be seen on imaging).
- You have good organ function (heart, lungs, kidneys, liver) and a performance score of 60% or higher (meaning you can do most daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
This trial tests a one-time, lab-made immune cell treatment (CD19 CAR-T) for certain B-cell blood cancers in children and young adults. It may help people whose leukemia or lymphoma is not responding to standard treatment or has come back.
This trial tests a new CAR-T cell therapy for children, teens, and young adults with acute lymphoblastic leukemia that has not responded to standard treatment. The goal is to see if the therapy can put the leukemia into remission so the patient may then have a stem cell transplant.
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
This trial tests a locally made CAR T-cell therapy that targets CD19 on cancer cells. It is for children and young adults with certain B-cell cancers that have come back or not responded to other treatments.
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
Hear when a new B-Cell Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.